Contact us
CoFlo Medical double-barrel injector

Inject the
uninjectable

Our core annular flow technology removes the viscosity constraint from drug delivery, so concentration stops setting the terms of delivery.

How CoFlo works

Deliver any viscosity

Conventional injection force rises with viscosity until it becomes impossible. Core annular flow breaks that relationship: a thin sheath of low-viscosity fluid shields the drug from the needle wall, where shear is highest, so concentration stops being a limit on delivery.

Beyond

1,000 cP

Injection force versus core viscosity On a log scale of core viscosity from 10 to over 1000 cP, injection force for conventional devices rises steeply, while injection force for CoFlo devices stays flat and low. 10 100 1000 Core viscosity (cP) Injection force (N) Conventional Devices CoFlo Devices
Read the white paper

Introducing core annular flow technology

In conventional injections, viscous drag along the needle wall slows injection. With core annular flow, sheath fluid shields the drug from the needle, streamlining delivery.

Conventional

Core Annular Flow

Break the injectability barrier

  1. 01

    IV to subcutaneous conversion

    Turn hours-long hospital infusions into 10-second injections at home.

  2. 02

    Dual-drug co-delivery

    Administer two formulations in a single injection.

  3. 03

    Extended dosing intervals

    Supports higher per-dose concentrations and conjugated formats.

  4. 04

    Reduced injection burden

    Reduce injection volume and time without compromising complexity.

  5. 05

    Broader candidate viability

    Carry candidates forward that viscosity would otherwise have ruled out. Gentle delivery for shear-sensitive compounds.

We're working with many of the world's top pharmas on advanced formulations that challenge the limits of conventional delivery.

Partner contact

Core Annular Flow
Device Platforms

Core annular flow is a physical solution that changes how a drug moves through the needle, not what the drug is. It serves as a platform across molecule types, volumes, and routes of administration.

The CoFlo Gen One hub on a syringe beside the CoFlo double-barrel device with its CO-AXL hub

  1. Gen One hub

    Sheath fluid is stored in the needle hub and is entrained during delivery.

  2. Double barrel

    Two syringes hold the sheath fluid and viscous fluid before they form a core annular flow in the CO-AXL Hub.

  3. CO-AXL hub

    Adapts two syringes to form the core annular flow.

We aim to make life-saving therapies easier to give and easier to get.

Join our team
  • Simon Rufer

    Simon Rufer

    CEO & Co-founder

    During his MIT PhD, Simon uncovered the fundamental fluidic phenomena that stabilize core-annular flows and built the prototypes behind CoFlo's platform. He draws on prior engineering experience at SpaceX and JPL to lead scale-up and commercialization.

  • Vishnu Jayaprakash

    Vishnu Jayaprakash

    CBO & Co-Founder

    Vishnu is an experienced startup executive, having founded and led several ventures including AgZen, where he scaled RealCoverage, a first-of-its-kind vision system for adjuvant spraying, to over 1 million acres internationally. Vishnu completed his PhD at MIT in interfacial phenomena, where he led the development of early core-annular flow injectors.

  • Kripa Varanasi

    Kripa Varanasi

    Co-Founder & Chairman

    Kripa is an MIT Professor of Mechanical Engineering whose work on interfacial phenomena has driven innovations in the medical, energy, water, and agriculture industries. He was previously a lead researcher and project leader at GE Global Research, and has co-founded several startups earning numerous awards.

  • Darius Moshfeghi

    Darius Moshfeghi

    Chief Medical Advisor, Ophthalmology

    Dr. Moshfeghi is Professor of Ophthalmology and Chief of Retina at Stanford's Byers Eye Institute. He founded Stanford's vitreoretinal surgery fellowship and established SUNDROP, a telemedicine program for retinopathy of prematurity screening. As a practicing vitreoretinal surgeon, he brings direct experience with ophthalmic procedures and intravitreal delivery, along with experience in clinical trial oversight, steering committees, and ophthalmology product development.

Latest from CoFlo

Inject the uninjectable

Contact us